)
)
)
Gipfel Biotechnology Limited
Gipfel Biotechnology (Cayman-registered) is the 100% owner of Hangzhou Qiandai Biotechnology (est. 2023, Hangzhou). Our R&D portfolio covers two core areas:
- Innovative small-molecule drugs for ophthalmic diseases, autoimmune diseases, chronic kidney disease and hyperuricemia;
- Recombinant subunit vaccines targeting respiratory infections (e.g., Mycoplasma pneumoniae—a PCC-stage candidate with confirmed efficacy and safety).
To date, three proprietary pre-clinical candidates have advanced to PCC stage, with their efficacy and safety validated in animal models. Additional vaccine candidates are under screening to meet unmet medical needs.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)